Literature DB >> 2035026

LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.

S Wain-Hobson1, J P Vartanian, M Henry, N Chenciner, R Cheynier, S Delassus, L P Martins, M Sala, M T Nugeyre, D Guétard.   

Abstract

Two of the first human immunodeficiency virus type-1 (HIV-1) strains isolated were authenticated by reanalyzing original cultured samples stored at the Collection Nationale de Culture des Microorganismes as well as uncultured primary material. Cloned polymerase chain reaction products were used to analyze coding sequences of the V3 loop in the gp120 glycoprotein. The original isolate HIV-1 Bru, formerly called LAV, was derived from patient BRU. HIV-1 Lai was derived from patient LAI and contaminated a HIV-1 Bru culture between 20 July and 3 August 1983. The culture became, in effect, HIV-1 Lai, identifiable by a unique motif in the V3 loop. Because of this contamination two, rather than one, HIV-1 isolates were sent to the Laboratory of Tumor Cell Biology at the National Cancer Institute on 23 September 1983. Original HIV-1 Bru was indeed present in the sample marked JBB/LAV. However the M2T-/B sample harbored HIV-1 Lai, a strain capable of growing on established cell lines. The striking similarity between HIV-1 Lai (formerly LAV-Bru) and HTLV-3B sequences remains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2035026     DOI: 10.1126/science.2035026

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  67 in total

1.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo.

Authors:  L P Martins; N Chenciner; B Asjö; A Meyerhans; S Wain-Hobson
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

4.  Strand specific PCR amplification of low copy number DNA.

Authors:  A Meyerhans; J P Vartanian; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1992-02-11       Impact factor: 16.971

5.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

6.  Spatial discontinuities in human immunodeficiency virus type 1 quasispecies derived from epidermal Langerhans cells of a patient with AIDS and evidence for double infection.

Authors:  M Sala; G Zambruno; J P Vartanian; A Marconi; U Bertazzoni; S Wain-Hobson
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.

Authors:  E Wattel; J P Vartanian; C Pannetier; S Wain-Hobson
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.